[TKI 2.0 - changes in the medical treatment of renal cell carcinoma]. / TKI 2.0 Wandel in der medikamentösen Therapie des Nierenzellkarzinoms.
Urologe A
; 57(3): 314-322, 2018 Mar.
Article
em De
| MEDLINE
| ID: mdl-28879504
ABSTRACT
Only for renal cell carcinoma (RCC) in a local stage curative treatment option by surgical resection exists. For metastatic disease the 5year survival rate decreases radically. A factor that contributes to this is the low sensibility to radiation and chemotherapeutics. Since the approval of the tyrosine kinase inhibitors in 2006 effective drugs for the treatment of mRCC is available. The specific inhibition of the vascular-endothelial-growth (VEGF)-receptor and the "mammalian Target of Rapamycin" (mTOR) leads to a prolongation of the progression-free survival as well as the overall survival rate. For a long time, the current target therapy with TKI appeared to be exhausted, but since recently research has gone a step further. Thus, Cabozantinib and Lenvatinib in the combination with Everolimus have been approved for second-line therapy in mRCC. For the first time a clinical study demonstrated positive results for an adjuvant treatment with sunitinib in patients with a high-risk RCC. Furthermore, in april 2016 the immune checkpoint inhibitor Nivolumab was approved for second-line therapy in mRCC in Germany. The following report examines briefly the current therapeutic recommendations, new findings and drug approvals and ongoing clinical trials.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Carcinoma de Células Renais
/
TYK2 Quinase
/
Everolimo
/
Neoplasias Renais
/
Antineoplásicos
Tipo de estudo:
Guideline
Limite:
Animals
/
Humans
País/Região como assunto:
Europa
Idioma:
De
Ano de publicação:
2018
Tipo de documento:
Article